MedicaidPrior AuthMedium impact
Erwinase® (asparaginase Erwinia chrysanthemi) (New)
Humana·IN · Oncology, Hematology, Pediatrics·Medicaid
Effective date
Nov 1, 2025
We identified it
Jun 24, 2026
Summary
Humana Medicaid Indiana has implemented a new prior authorization policy for Erwinase (asparaginase Erwinia chrysanthemi), an oncology medication for acute lymphoblastic leukemia patients who have experienced hypersensitivity to other asparaginase therapies. Prior authorization is required with specific clinical criteria including documented Grade 2-4 hypersensitivity to Oncaspar and use as part of multi-agent chemotherapy.
Action Required
Before November 1, 2025: Providers treating ALL patients must obtain prior authorization for Erwinase prescriptions through Humana Medicaid Indiana. Ensure documentation includes: diagnosis of ALL, Grade 2-4 hypersensitivity to pegaspargase, and confirmation of multi-agent chemotherapy regimen. Update pharmacy ordering systems to flag this medication for prior auth requirements.